Daxor to Present at the Inaugural Sepsis Alliance Summit
September 15 2020 - 8:30AM
Daxor Corporation (NYSE MKT: DXR), an investment company with
innovative medical instrumentation and biotechnology operations
focused on blood volume measurement, today announces the Company
will be participating in the inaugural Sepsis Alliance Summit.
Michael Feldschuh, President and Chief Executive Officer of Daxor,
will present as part of a Panel Discussion: Connecting Innovation
to Clinicians: The Development Story to Improve Sepsis Care on
Thursday, September 17th, 2020, at 1:30 PM ET.
“I am honored to be invited to participate in
this important event to discuss how our BVA-100 blood test can
provide insights into volume derangements and capillary
permeability in critically-ill patients with sepsis,” said Michael
Feldschuh, President and CEO of Daxor. “The albumin transudation
rate which is a unique metric of the BVA-100 test is an indicator
of the rate at which fluids may be escaping the intravascular space
- a persistently elevated leak rate is a prognostic marker
associated with a higher mortality and can be used to triage
patients, guide treatment and measure response to
interventions.”
Dozens of peer-reviewed studies have established
the value of Daxor’s BVA-100 test, confirming that accurate blood
volume measurement leads to better informed physicians, improved
patient outcomes and resource utilization. In a randomized control
trial conducted at a Level-1 trauma center on patients suffering
predominantly from ARDS/sepsis/septic shock/hemorrhagic shock;
patients who received BVA guided care showed significant benefits
including 66% lower mortality, days on ventilators, and ICU length
of stay.
Event: The Inaugural Sepsis Alliance SummitDate: Thursday,
September 17th, 2020Presentation: 1:30 PM ETRegister for the event
here: https://whova.com/web/sepsi_202008/
Additionally, Daxor would also like to highlight
that September is National Sepsis Awareness Month. Sepsis is the
number one inpatient cost and estimated to cost $27 billion per
year. According to the CDC, each year, at least 1.7 million adults
in America develop sepsis. Nearly 270,000 Americans die as a result
of sepsis. 1 in 3 patients who dies in a hospital has sepsis.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is an innovative
medical instrumentation and biotechnology company focused on blood
volume measurement. We developed and market the BVA-100® (Blood
Volume Analyzer), the first diagnostic blood test cleared by the
FDA to provide safe, accurate, objective quantification of blood
volume status and composition compared to patient-specific norms.
The BVA technology has the potential to improve hospital
performance metrics in a broad range of surgical and medical
conditions, including heart failure and critical care, by informing
treatment strategies, resulting in significantly improved patient
outcomes. Our mission is to partner with clinicians to incorporate
BVA technology into standard clinical practice and improve the
quality of life for patients. For more information, please visit
our website at Daxor.com
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret ShapiroSr. Managing
Partner, CORE IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Apr 2023 to Apr 2024